Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies worldwide. Its product portfolio includes aesthetic device platforms, including Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Velocity and Venus Epileve, a diode laser device for hair removal, permanent hair reduction, and treatment of ingrown hair; and Venus Fiore that is used for the treatment of vaginal canal, labia skin tightening, and mons pubis. The company also offers Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin; Venus Freeze Plus, a noninvasive device used in dermatologic and general surgical procedures for females for the noninvasive treatment of moderate to severe facial wrinkles and rhytides; Venus Bliss, a device is used for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance. In addition, it provides NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system; and ARTAS and ARTAS iX, a robotic systems to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
IPO Year: 2017
Exchange: NASDAQ
Website: venusconcept.com
TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume
TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in
TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med
8-K - Venus Concept Inc. (0001409269) (Filer)
8-K - Venus Concept Inc. (0001409269) (Filer)
DEF 14A - Venus Concept Inc. (0001409269) (Filer)
8-K - Venus Concept Inc. (0001409269) (Filer)
PRE 14A - Venus Concept Inc. (0001409269) (Filer)
8-K - Venus Concept Inc. (0001409269) (Filer)
10-Q - Venus Concept Inc. (0001409269) (Filer)
8-K - Venus Concept Inc. (0001409269) (Filer)
8-K - Venus Concept Inc. (0001409269) (Filer)
EFFECT - Venus Concept Inc. (0001409269) (Filer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
4 - Venus Concept Inc. (0001409269) (Issuer)
TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2024. Summary of Financial Results & Recent Progress: Company continues to execute against Transformation Plan Cash used in operations for the first nine months of 2024 of $7.3 million, down 40% year-over-year Total revenue for the third quarter of $15.0 million, down 15% year-over-year, and below third quarter estimate of at "least $17.0 million". Third quarter operating expenses declined 10% year-over-year; limiting GAAP operating loss to 6% year
TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced the continued expansion of its international distributor network with several developments globally: Index International Ltd., a subsidiary of Paragon Meditech ("Paragon"), in TaiwanQuirugil S.A ("Quirugil"), in ColombiaCertification of select products in India with the Company's exclusive distribution partner, Spectra Medical Systems ("Spectra") Founded in 2014, Paragon currently operates under three banners covering China, Hong Kong and Taiwan with a total of more than 130 total employees. Paragon brings extensive ae
TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, November 13, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2024 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13749236. A live webcast of the call will also be provided on the investor relations section of the Company's
TORONTO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that, on September 26, 2024, the Company exchanged $15.0 million of its senior debt held by affiliates of Madryn Asset Management, LP ("Madryn") for 203,583 shares of its Series Y preferred stock. Following this transaction, the Company had total debt obligations of approximately $34.6 million, down 25% from $46.0 million outstanding as of June 30, 2024 and down 54% from $74.9 million outstanding as of December 31, 2023. "We continue to execute on our transformation plan and today's transaction brings us another step
TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that it has clearance from the Therapeutic Goods Administration (TGA) in Australia to market the Venus Bliss MAX system. The Venus Bliss MAX is the Company's flagship platform that offers a comprehensive, world-class solution for all customers' body treatment needs and is currently available in select markets globally. Featuring three of Venus Concept's market leading technologies in one, the Venus Bliss MAX is a body shaping solution consisting of our proprietary (MP)2 applicator that combines Multi-Polar Radio Fr
TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2024. Second Quarter 2024 Summary & Recent Progress: Company continues to execute against Transformational Plan Cash used in operations of $1.3 million, down 37% year-over-year and down 54% quarter-over-quarter Total revenue of $16.6 million, down 17% year-over-year, but in-line with second quarter estimate of at "least $16.5 million". Gross margin up 62 basis points year-over-year to 71.5%, combined with a 13% decrease in operating expenses year-over-year, dri
TORONTO, July 29, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that it has received a medical device license issued by Health Canada to market the Venus Bliss MAX system in Canada. The Venus Bliss MAX was first available in the United States in early 2022 and subsequently offered in approved jurisdictions around the world. The Venus Bliss MAX is a 3-in-1 body shaping solution featuring three of Venus Concept's market leading technologies in one complete platform, including diode laser for Fat Reduction treatments, our proprietary (MP)2 applicator that combines Multi-Polar Radio F
TORONTO, July 15, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2024 financial results will be released before the market opens on Tuesday, August 13, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on August 13, 2024 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13747737. A live webcast of the call will also be provided on the investor relations section of the Company's webs
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announces the successful completion of its NEXThetics events held across several major cities in North America. NEXThetics events bring together Venus Concept's network of aesthetic leaders and practitioners and have seen a significant increase in popularity and attendance. Since our pilot events, the Company has hosted thousands of registrants, including its largest gathering to date in Houston, Texas on June 22, 2024. "NEXThetics Houston was an outstanding event, centering on the core principles of the latest technology, networking
TORONTO, June 17, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that it has entered a new strategic resurfacing and skin tightening device supply arrangement with Skin Laundry Holdings, Inc. ("Skin Laundry"). The supply arrangement included an initial order for Venus Viva ("Viva") devices for their locations across the United States and the associated Viva tips consumable to complete the procedures. Skin Laundry is placing the devices throughout their chain of clinics and plans to perform thousands of skin resurfacing treatments per month using Venus Concept's proprietary (MP)2 Nan
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13G/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13G/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
SC 13D/A - Venus Concept Inc. (0001409269) (Subject)
TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, November 13, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2024 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13749236. A live webcast of the call will also be provided on the investor relations section of the Company's
TORONTO, July 15, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2024 financial results will be released before the market opens on Tuesday, August 13, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on August 13, 2024 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13747737. A live webcast of the call will also be provided on the investor relations section of the Company's webs
TORONTO, April 15, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, May 15, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2024, to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13745887. A live webcast of the call will also be provided on the investor relations section of the Company's website
TORONTO, April 01, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2023. Fourth Quarter and Fiscal Year 2023 Summary & Recent Progress: Company continues to execute against Transformational Plan and achieved primary objective of reducing cash burn by over 50% vs. prior year Cash used in operations for fiscal year 2023 of $12.9 million, down 52% year-over-year, from $27.0 million in the prior year periodCash system revenue for fiscal year 2023 represented approximately 67% of total systems and subscriptions revenu
TORONTO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2023 financial results will be released before the market opens on Monday, April 1, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on April 1, 2024 to discuss the results of the quarter and the year with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13744647. A live webcast of the call will also be provided on the investor relations section of the
TORONTO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2023. Third Quarter 2023 Summary & Recent Progress: Company continues to execute against Transformational Plan Total revenue of $17.6 million, down $3.9 million, or 18%, year-over-yearCash system revenue represented approximately 69% of total systems and subscriptions revenue, compared to 59% in the prior year periodOperating expenses of $18.9 million, including approximately $0.8 million of costs related to restructuring activities, down $5.9 million, or
TORONTO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2023 financial results will be released after the market closes on Tuesday, November 14, 2023. Management will host a conference call at 5:00 p.m. Eastern Time on November 14, 2023 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13741931. A live webcast of the call will also be provided on the investor relations section of the Company's w
TORONTO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2023. Second Quarter 2023 Summary & Recent Progress: Company continues to execute against Transformational Plan Total revenue of $20.1 million, down $7.2 million, or 26%, year-over-yearCash system revenue represented approximately 74% of total systems and subscriptions revenue, compared to 49% in the prior year periodOperating expenses of $20 million, including approximately $0.4 million of costs related to restructuring activities, down $6.2 mil
TORONTO, July 05, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2023 financial results will be released after the market closes on Monday, August 14, 2023. Management will host a conference call at 5:00 p.m. Eastern Time on August 14, 2023 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13739854. A live webcast of the call will also be provided on the investor relations section of the Company's websi
TORONTO, May 15, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2023. First Quarter 2023 Summary & Recent Highlights: Company continues to execute against Transformational Plan Total revenue of $20.5 million, down $5.9 million, or 22%, year-over-yearCash system revenue represented approximately 66% of total systems and subscriptions revenue, compared to 53% in the prior year periodOperating expenses of $21.9M, including approximately $0.9 million of costs related to restructuring activities, down $3.3M or 13% year-over-yearCash use